IP Library › Granted Patent US 8,455,449
Granted Patent B2
US 8,455,449 · App. 13/589,017 · Granted Jun 4, 2013

Compositions and methods for modulating γ-c-cytokine activity

Inventors: Yutaka Tagaya (Rockville, MD); Nazli Azimi (San Juan Capistrano, CA)
Assignee: Bioniz, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,455,449
App. No.
13/589,017
Granted
Jun 4, 2013
Kind
B2
Abstract

The γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. The present embodiments relate to the design of peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. In several embodiments, peptide antagonists exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.

Claims (7)

1. An isolated or purified peptide comprising amino acid sequence I-K-E-F-L-Q-R-F-I-H-I-V-Q-S-I-I-N-T-S (SEQ ID NO: 1), wherein the peptide inhibits the activity of one or more γc-cytokines selected from the group consisting of: IL-2, IL-4, IL-7, IL-9, IL-15 or IL-21.

2. The isolated or purified peptide of claim 1 , wherein the isolated or purified peptide further comprises a conjugate at the N-termini, C-termini or side residues of the peptide.

3. The isolated or purified peptide of claim 2 , wherein the conjugate is selected from the group consisting of: bovine serum albumin (BSA), albumin, Keyhold Limpet Hemocyanin (KLH), Fc region of IgG, a biological protein that functions as scaffold, an antibody against a cell-specific antigen, a receptor, a ligand a metal ion and Poly Ethylene Glycol (PEG).

4. The isolated or purified peptide of claim 1 , wherein the isolated or purified peptide further comprises a signal peptide.

5. The isolated or purified peptide of claim 1 , wherein the isolated or purified peptide further comprises a peptide that stabilizes the structure of the peptide and improves its biological activity.

6. The isolated or purified peptide of claim 1 , wherein the isolated or purified peptide further comprises one or more pharmaceutically acceptable diluents, emulsifying compounds, solubilizers, adjuvants, and carriers.

7. The isolated or purified peptide of claim 1 , wherein the isolated or purified peptide consists essentially of amino acid sequence I-K-E-F-L-Q-R-F-I-H-I-V-Q-S-I-I-N-T-S (SEQ ID NO: 1).

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Oct 6, 2023
From: BIONIZ, LLC; BIONIZ THERAPEUTICS, INC.
To: BIONIZ THERAPEUTICS, INC.
Reel/Frame 065153/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2012
From: TAGAYA, YUTAKA; AZIMI, NAZLI
To: BIONIZ, LLC
Reel/Frame 028846/0952 →
Continuity (4)
Continuation In Part PCTUS2012021566 · Jan 17, 2012
Provisional Application 61433890 · Jan 18, 2011
Provisional Application 61527049 · Aug 24, 2011
Related Publication 20120329728A1 · Dec 27, 2012